Technology, Healthcare, Financials Jan 13, 2022 10:49 AM (GMT+8) · EqualOcean
Yiouda health learned on the 13th that Jiangsu care medical, a domestic membrane science platform enterprise in the pharmaceutical field, announced that it had completed the round B financing of hundreds of millions of yuan jointly led by Boyuan capital and Sherpa investment, followed by cornerstone capital and Wuzhong biomedical industry fund, and Bairong capital acted as the sole financial adviser for this round of financing. This round of financing will be used for the continuous R & D investment of caring medical in the field of membrane science platform, the capacity improvement of biopharmaceutical membrane and filter column assembly line and the market promotion of related products. Care medical is a platform enterprise committed to improving the innovation ability and manufacturing level of Membrane Science in China. At present, the main products of care medical are high-end membrane materials and components such as nanofiltration, ultrafiltration, microfiltration and reverse osmosis, which are mainly used in biopharmaceutical related fields such as vaccine, cell therapy, antibody drugs and gene therapy, as well as blood purification. It has the whole industrial chain capacity from raw material formulation, membrane production line manufacturing and assembly, membrane production and filter column finished product assembly and sales.

This text is a result of machine translation.